Uncategorized
Peeling Back The Layers: Exploring Atlassian Through Analyst Insights
Latest Ratings for TEAM Date Firm Action From To Jan 2022 Cowen & Co. Maintains Market Perform Jan 2022 Cowen & Co. Maintains Market Perform Dec 2021 Goldman Sachs Initiates Coverage On Neutral View More Analyst Ratings for TEAM View the Latest Analyst Ratings read more
Five Below Analyst Highlights Growth, Store Economics: ‘We Want To Be Bullish’
Five Below reported better-than-expected third-quarter results on Wednesday. Truist analyst Scot Ciccarelli weighs in on the report and what could lie ahead for the retailer. Latest Ratings for FIVE Date Firm Action From To Mar 2022 UBS Upgrades Neutral Buy Jan 2022 Keybanc Upgrades Sector Weight Overweight Jan 2022 Truist Securities Initiates Coverage On Buy…
Campbell’s Company Faces Potential Earnings Risk Due To Consumer Challenges: Analysts
Analysts express concerns over consumer challenges for Campbell’s Company (CPB), lowering EPS estimates while noting potential risks to earnings and long-term growth opportunities. Latest Ratings for CPB Date Firm Action From To Mar 2022 Citigroup Maintains Neutral Mar 2022 RBC Capital Maintains Outperform Jan 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for CPB…
Mag 7’s AI Boom Will Supercharge Natural Gas Sector As Power Demands Become Insatiable: Analyst
AI’s surge in power demand is making natural gas a top energy choice. U.S. LNG exports and tech-driven capex frenzy are driving its growth. read more
Cannabis-Focused Poseidon Bets On New Jersey, Wraps Up Investments In These Two Dispensaries
Poseidon Investment Management announced on Wednesday that it has completed two investments into two New Jersey dispensaries, BLKBRN and Dogwood Green. Both businesses are focused on serving both patients and recreational cannabis consumers when they open in 2025.”With these two investments, we are allocating to retail in special situations, driving outsized sales with a focus…
Merus Scores Its First FDA Approval For Lung Cancer Drug
FDA approves Merus’ Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million. Latest Ratings for MRUS Date Firm Action From To Feb 2022 BMO Capital Initiates Coverage On Outperform Feb 2022 Needham Initiates Coverage On Buy Nov 2021 HC Wainwright & Co. Maintains Buy View More…
